BCYC

Bicycle Therapeutics Ltd

BCYC.US bicycletherapeutics.com + Research + Basket
CIK 0001761612
Employees 288
Phone 44 1223 261 503
Fiscal year end December
IPO May 23, 2019
Address Portway Building, Cambridge, United Kingdom, CB21 6GS
3.70
-0.12 (-3.14%)
USD · NASDAQ
52-week range
3.33
8.11
Trading at 8% of the 52-week range
Market Cap
267.37M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
7.31
Div. Yield
N/A
% Institutions
71.68%
% Insiders
4.59%

1 Year

-53.3%

3 Year

-74.3%

10 Year

-68.2%
Description

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Actions

Add an action for BCYC.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Kevin Lee M.B.A., Ph.D. CEO & Executive Director 1968
Dr. Michael Skynner B.sc. Ph.d., Ph.D. Chief Scientific Officer 1969
Mr. Alistair Milnes Chief Corporate Development Officer 1974
Dr. Christian Heinis Scientific Founder NA
Mr. Travis Thompson Chief Financial Officer 1980
Dr. Jennifer Perry Pharm.D. Chief Operating Officer 1974
Ms. Stephanie Yao Senior Vice President of Investor Relations and Corporate Communications NA
Mr. Zafar Qadir Chief Legal Officer & General Counsel NA
Dr. Phil Jeffrey Senior VP of Pre-Clinical Development NA
Dr. Michael Charles-Ferguson Hannay Chief Product & Supply Chain Officer 1966

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 06, 2026 Kevin Lee N/A Sale 1.72K $5.05 $8.67K SEC
Apr 06, 2026 Travis Alvin Thompson N/A Sale 102.00 $5.05 $515.10 SEC
Apr 06, 2026 Jennifer Scott Perry N/A Sale 370.00 $5.04 $1.86K SEC
Apr 02, 2026 Jennifer Scott Perry N/A Sale 1.04K $4.91 $5.10K SEC
Apr 02, 2026 Kevin Lee N/A Sale 5.97K $4.91 $29.30K SEC
Apr 02, 2026 Travis Alvin Thompson N/A Sale 799.00 $4.91 $3.92K SEC
Jan 05, 2026 Alethia Young N/A Sale 4.33K $6.49 $28.13K SEC
Jan 05, 2026 Alistair Milnes N/A Sale 3.42K $6.46 $22.07K SEC
Jan 05, 2026 Kevin Lee N/A Sale 10.99K $6.46 $70.99K SEC
Jan 05, 2026 Travis Alvin Thompson N/A Sale 1.12K $6.45 $7.19K SEC
Jan 02, 2026 Alethia Young N/A Sale 3.29K $6.80 $22.37K SEC
Jan 02, 2026 Alistair Milnes N/A Sale 3.24K $6.80 $22.06K SEC
Jan 02, 2026 Kevin Lee N/A Sale 10.33K $6.80 $70.21K SEC
Jan 02, 2026 Travis Alvin Thompson N/A Sale 1.32K $6.80 $8.96K SEC
Oct 03, 2025 Alistair Milnes N/A Sale 978.00 $8.41 $8.22K SEC
Oct 03, 2025 Travis Alvin Thompson N/A Sale 103.00 $8.41 $866.23 SEC
Oct 03, 2025 Kevin Lee N/A Sale 3.23K $8.41 $27.17K SEC
Oct 02, 2025 Alethia Young N/A Sale 482.00 $8.51 $4.10K SEC
Oct 02, 2025 Alistair Milnes N/A Sale 1.15K $8.40 $9.63K SEC
Oct 02, 2025 Kevin Lee N/A Sale 2.26K $8.40 $19.01K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Baker Bros Advisors LP 10.89M Jun 30, 2026 15.55% $0.23 0.00%
FCPM III SERVICES BV 3.47M Jun 30, 2026 4.96% $1.96 0.00%
Armistice Capital, LLC 3.40M Jun 30, 2026 4.85% $0.18 0.00%
Long Focus Capital Management, LLC 3.31M Jun 30, 2026 4.73% $0.36 0.00%
Acadian Asset Management LLC 1.97M Jun 30, 2026 2.81% $0.01 0.00%
Renaissance Technologies Corp 1.53M Jun 30, 2026 2.19% $0.01 56.58%
GSK PLC 1.53M Jun 30, 2026 2.19% $1.08 0.00%
T. Rowe Price Associates, Inc. 902.15K Jun 30, 2026 1.29% $0.00 -12.26%
Marshall Wace Asset Management Ltd 797.94K Jun 30, 2026 1.14% $0.00 111.47%
Qube Research & Technologies 775.57K Jun 30, 2026 1.11% $0.00 151.30%
Morgan Stanley - Brokerage Accounts 667.27K Jun 30, 2026 0.95% $0.00 7.92%
Schroder Investment Management Group 615.83K Jun 30, 2026 0.88% $0.00 0.00%
Citadel Advisors Llc 554.23K Jun 30, 2026 0.79% $0.00 46.98%
Millennium Management LLC 553.97K Jun 30, 2026 0.79% $0.00 95.07%
Peapod Lane Capital LLC 537.98K Jun 30, 2026 0.77% $1.54 344.22%
Diadema Partners LP 462.72K Jun 30, 2026 0.66% $0.25 -2.88%
Two Sigma Investments LLC 434.58K Jun 30, 2026 0.62% $0.00 163.70%
Jane Street Group LLC 392.16K Jun 30, 2026 0.56% $0.00 79.80%
FLAX POND CAPITAL, LLC 376.22K Jun 30, 2026 0.54% $0.62 113.60%
Birchview Capital, LP 313.62K Jun 30, 2026 0.45% $0.62 -32.35%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 International Biotechnology Ord 615.83K 0.88% ▲ 0.00% Jun 30, 2026
2 iShares Biotechnology ETF 291.59K 0.42% ▼ 0.75% Sep 30, 2026
3 Old Westbury Small & Mid Cap Strategies 265.97K 0.38% ▲ 0.00% Jul 31, 2026
4 Virtus LifeSci Biotech Clinical Trls ETF 78.35K 0.11% ▲ 0.00% Sep 30, 2026
5 ALPS Medical Breakthroughs ETF 66.50K 0.10% ▲ 0.00% Sep 30, 2026
6 PPF Helix Biotechnology I USD 58.30K 0.08% ▲ 0.00% Jun 30, 2026
7 TD Health Sciences - I 46.00K 0.07% ▲ 0.00% Jun 30, 2026
8 iShares Nasdaq US Biotech ETF USD Acc 38.01K 0.05% ▲ 0.87% Sep 30, 2026
9 State Street® SPDR® S&P® Intl Sm Cp ETF 37.23K 0.05% ▲ 0.00% Sep 30, 2026
10 Voya Multi-Manager International Sm Cp A 30.05K 0.04% ▲ 0.00% Jun 30, 2026

Financial Highlights

▼
Market Cap: $267.37M
EBITDA: $-200.81M
Book Value: $7.31
Earnings/Share: $-2.73
Profit Margin: 0.00%
Operating Margin: -8,673.93%
ROA (TTM): -17.91%
ROE (TTM): -32.30%
Revenue (TTM): $61.21M
Revenue/Share (TTM): $0.88
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -78.50%

Valuation Metrics

Enterprise Value: $-223.82M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 50.55M
Shares Float: 7.76M
% Insiders: 4.59%
% Institutions: 71.68%
Shares Short: 3.45M
Shares Short (Prior Month): 3.30M
Short Ratio: 7.22
Short % Float: 8.84%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$72.59M
Cost of Goods Sold
adjust
$-6.44M
Gross Profit
subtotal
$72.59M
SG&A
adjust
$-80.02M
R&D
adjust
$-240.28M
Operating Income
subtotal
$-247.72M
Other / Non-Operating Items
adjust
$28.76M
Net Income
subtotal
$-218.96M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BCYC.US!